CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in cases of neuropathic pain
3.4.1.2. Rise in prevalence of chronic diseases
3.4.1.3. Rise in geriatric population
3.4.2. Restraints
3.4.2.1. Side effects of neuropathic pain medicine
3.4.3. Opportunities
3.4.3.1. Rise in number of drugs in pipeline
CHAPTER 4: NEUROPATHIC PAIN MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Antidepressants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Antidepressants Neuropathic Pain Market by Type
4.3. Anticonvulsant
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Opioids
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Capsaicin
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: NEUROPATHIC PAIN MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Diabetic Neuropathy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Spinal Stenosis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Chemotherapy-Induced Peripheral Neuropathy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drugs Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: NEUROPATHIC PAIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug class
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug class
7.2.5.1.2. Market size and forecast, by Indication
7.2.5.1.3. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug class
7.2.5.2.2. Market size and forecast, by Indication
7.2.5.2.3. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug class
7.2.5.3.2. Market size and forecast, by Indication
7.2.5.3.3. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug class
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug class
7.3.5.1.2. Market size and forecast, by Indication
7.3.5.1.3. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug class
7.3.5.2.2. Market size and forecast, by Indication
7.3.5.2.3. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug class
7.3.5.3.2. Market size and forecast, by Indication
7.3.5.3.3. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug class
7.3.5.4.2. Market size and forecast, by Indication
7.3.5.4.3. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug class
7.3.5.5.2. Market size and forecast, by Indication
7.3.5.5.3. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug class
7.3.5.6.2. Market size and forecast, by Indication
7.3.5.6.3. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug class
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Drug class
7.4.5.1.2. Market size and forecast, by Indication
7.4.5.1.3. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Drug class
7.4.5.2.2. Market size and forecast, by Indication
7.4.5.2.3. Market size and forecast, by Distribution channel
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Drug class
7.4.5.3.2. Market size and forecast, by Indication
7.4.5.3.3. Market size and forecast, by Distribution channel
7.4.5.4. India
7.4.5.4.1. Market size and forecast, by Drug class
7.4.5.4.2. Market size and forecast, by Indication
7.4.5.4.3. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Drug class
7.4.5.5.2. Market size and forecast, by Indication
7.4.5.5.3. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Drug class
7.4.5.6.2. Market size and forecast, by Indication
7.4.5.6.3. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug class
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug class
7.5.5.1.2. Market size and forecast, by Indication
7.5.5.1.3. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Drug class
7.5.5.2.2. Market size and forecast, by Indication
7.5.5.2.3. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Drug class
7.5.5.3.2. Market size and forecast, by Indication
7.5.5.3.3. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Drug class
7.5.5.4.2. Market size and forecast, by Indication
7.5.5.4.3. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Teva Pharmaceuticals
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Glenmark Pharmaceuticals Limited
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Mallinckrodt Pharmaceuticals
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Eli Lilly and Company.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Grunenthal GmbH.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Collegium Pharmaceutical Inc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Abbott Laboratories
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer